Neurocrine Biosciences, Inc. (NBIX)
142.70
-0.59
(-0.41%)
USD |
NASDAQ |
Oct 23, 16:00
142.71
+0.01
(+0.01%)
After-Hours: 20:00
Neurocrine Biosciences Price to Book Value : 3.925 for Oct. 23, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 3.925 |
| October 22, 2026 | 3.942 |
| October 21, 2026 | 3.887 |
| October 20, 2026 | 3.906 |
| October 19, 2026 | 3.768 |
| October 16, 2026 | 3.733 |
| October 15, 2026 | 3.767 |
| October 14, 2026 | 3.738 |
| October 13, 2026 | 3.717 |
| October 12, 2026 | 3.889 |
| October 09, 2026 | 3.918 |
| October 08, 2026 | 3.885 |
| October 07, 2026 | 3.946 |
| October 06, 2026 | 4.002 |
| October 05, 2026 | 3.967 |
| October 02, 2026 | 3.938 |
| October 01, 2026 | 3.870 |
| September 30, 2026 | 3.902 |
| September 29, 2026 | 3.806 |
| September 28, 2026 | 3.863 |
| September 25, 2026 | 3.807 |
| September 24, 2026 | 3.822 |
| September 23, 2026 | 3.837 |
| September 22, 2026 | 3.913 |
| September 21, 2026 | 3.960 |
| Date | Value |
|---|---|
| September 18, 2026 | 4.022 |
| September 17, 2026 | 4.176 |
| September 16, 2026 | 4.112 |
| September 15, 2026 | 4.127 |
| September 14, 2026 | 4.325 |
| September 11, 2026 | 4.297 |
| September 10, 2026 | 4.307 |
| September 09, 2026 | 4.267 |
| September 08, 2026 | 4.267 |
| September 04, 2026 | 4.281 |
| September 03, 2026 | 4.356 |
| September 02, 2026 | 4.340 |
| September 01, 2026 | 4.312 |
| August 31, 2026 | 4.237 |
| August 28, 2026 | 4.238 |
| August 27, 2026 | 4.289 |
| August 26, 2026 | 4.307 |
| August 25, 2026 | 4.219 |
| August 24, 2026 | 4.210 |
| August 21, 2026 | 4.197 |
| August 20, 2026 | 4.207 |
| August 19, 2026 | 4.278 |
| August 18, 2026 | 4.242 |
| August 17, 2026 | 4.250 |
| August 14, 2026 | 4.201 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Amgen, Inc. | 20.32 |
| BioCryst Pharmaceuticals, Inc. | -- |
| Halozyme Therapeutics, Inc. | 99.81 |
| Iovance Biotherapeutics, Inc. | 8.671 |
| Precigen, Inc. | 50.85 |
Price to Book Value Related Metrics
| PE Ratio | 20.91 |
| PS Ratio | 4.375 |
| PEG Ratio | 0.206 |
| Price to Free Cash Flow | 18.18 |
| Price | 142.70 |
| Earnings Yield | 4.78% |
| Market Cap | 14.50B |
| PEGY Ratio | 0.206 |
| Operating PE Ratio | 18.31 |
| Normalized PE Ratio | 21.33 |